Created at	Source	Raw Value	Validated value
Nov. 16, 2021, 6:30 p.m.	usa	Geometric Mean Concentrations of SARS-CoV-2 Spike Protein-Specific Binding Antibodies;Geometric Mean Titers of Anti-Human Papillomavirus Types 6, 11, 16, 18, 31, 33, 45, 52, and 58;Percentage of Participants with at Least 1 Serious Adverse Event;Percentage of Participants with at Least 1 Solicited Injection-site Adverse Event;Percentage of Participants with at Least 1 Solicited Systemic AE;Percentage of Participants with at Least 1 Vaccine-Related SAE	Geometric Mean Concentrations of SARS-CoV-2 Spike Protein-Specific Binding Antibodies;Geometric Mean Titers of Anti-Human Papillomavirus Types 6, 11, 16, 18, 31, 33, 45, 52, and 58;Percentage of Participants with at Least 1 Serious Adverse Event;Percentage of Participants with at Least 1 Solicited Injection-site Adverse Event;Percentage of Participants with at Least 1 Solicited Systemic AE;Percentage of Participants with at Least 1 Vaccine-Related SAE